Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.
Semaglutide research just got a close look from the FLOW trial team. Their latest response tackles the question: does semaglutide interact with mineralocorticoid receptor antagonists (MRAs) in chronic kidney disease research? Short answer: no major surprises, but a few key details matter for anyone running studies with these compounds.
Diabetes Care
by Rossing P, Perkovic V, Rasmussen S et al.
“Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial. Rossing P(1)(2), Perkovic V(3), Rasmussen S(4), Mann JFE(5)(6); FLOW Investigator Group. Author information: (1)Steno Diabetes Center Copenhagen, Herlev, Denmark. (2)University of Copenhagen, Copenhagen, Denmark. (3)University of New South Wales, Sydney, Australia. (4)Novo Nordisk A/S, Søborg, Denmark. (5)University Hospital Erlangen, Erlangen, Germany. (6)KfH Kidney Centre, Munich, Germany.”
FLOW is a big kidney outcomes trial using semaglutide, a GLP-1 receptor agonist. Some researchers wondered if results might get muddled by patients also taking MRAs — common in this population. The FLOW investigators break it down clearly: they saw no evidence that MRAs messed with the action of semaglutide in the trial. Both groups (with and without MRAs) showed consistent effects.
Key takeaway: stacking semaglutide and MRAs in research settings looks straightforward, at least based on FLOW data. If you’re designing protocols or interpreting results, this means less worry about hidden drug-drug interactions skewing your observations.
A few practical notes for researchers:
The trial included a significant number of participants on MRAs, making these findings relevant for real-world experimental setups.
The effects of semaglutide held steady across MRA subgroups, so you don’t need to carve out separate analysis plans unless you’re chasing edge cases.
Careful documentation in your protocols matters — but the FLOW team’s latest response makes it easier to justify including both compounds.
For researchers sourcing semaglutide for renal studies, this is one less variable to stress over. Need to set up blinded dosing or manage multiple research compounds in your workflow? Check out our research tools for streamlined logistics.
No drama here — just solid reassurance that semaglutide stands on its own, even in complex research environments.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.